Intelligence · Clinical Pipeline
Regeneron UK Pipeline
All ClinicalTrials.gov programs at Regeneron UK — phase, modality, and trial IDs.
- Programs
- 493
Quick answer
Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
ZIV-Aflibercept
Regeneron UK Limited
Metastatic Uveal Melanoma
1 trial -
Ziv-Aflibercept
Regeneron UK Limited
Uveal Melanoma
1 trial -
aflibercept
Regeneron UK Limited
Neovascular (Wet) Age-Related Macular Degeneration
1 trial -
aflibercept + FOLFIRI
Regeneron UK Limited
Metastatic Colorectal Cancer
1 trial -
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Regeneron UK Limited
Macular Degeneration
1 trial -
casirivimab+imdevimab
Regeneron UK Limited
Healthy
2 trials -
casirivimab+imdevimab
Regeneron UK Limited
COVID-19
2 trials -
cemiplimab
Regeneron UK Limited
Carcinoma, Basal Cell
1 trial -
cemiplimab
Regeneron UK Limited
Melanoma
1 trial -
cemiplimab
Regeneron UK Limited
Cutaneous Basal Cell Carcinoma
1 trial -
cemiplimab
Regeneron UK Limited
Advanced Cutaneous Squamous Cell Carcinoma
1 trial -
cemiplimab (monotherapy)
Regeneron UK Limited
Relapsed Solid Tumor
1 trial -
dupilumab
Regeneron UK Limited
Chronic Sinusitis
1 trial -
dupilumab
Regeneron UK Limited
Allergic Bronchopulmonary Aspergillosis
1 trial -
evinacumab
Regeneron UK Limited
Hypertriglyceridemia
1 trial -
evinacumab
Regeneron UK Limited
Severe Hypertriglyceridemia (sHTG)
1 trial -
vidutolimod
Regeneron UK Limited
Merkel Cell Carcinoma
1 trial -
89Zr˗DFO˗REGN3504
Regeneron UK Limited
Advanced PD-L1 Positive Malignancies
1 trial -
89Zr˗DFO˗REGN5054
Regeneron UK Limited
Advanced Solid Tumor
1 trial -
ALN-ANG3
Regeneron UK Limited
Healthy Volunteers With Hyperlipidemia
1 trial -
ALN-APOC3
Regeneron UK Limited
Dyslipidemia
1 trial -
ALN-F1202
Regeneron UK Limited
Healthy Volunteer
1 trial -
ALN-PNP
Regeneron UK Limited
Nonalcoholic Fatty Liver Disease (NAFLD)
1 trial -
ALN-SNCA
Regeneron UK Limited
Parkinsons Disease
1 trial -
ASP8374
Regeneron UK Limited
Glioblastoma
1 trial -
AVE0005 (aflibercept)
Regeneron UK Limited
Colorectal Neoplasms
1 trial -
Aflibercept
Regeneron UK Limited
Neovascular Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Irvine-Gass Syndrome
1 trial -
Aflibercept (AVE0005)
Regeneron UK Limited
Neoplasm Malignant
2 trials -
Aflibercept every 2 months
Regeneron UK Limited
Radiation Retinopathy
1 trial -
Alirocumab
Regeneron UK Limited
Sepsis
1 trial -
Alirocumab
Regeneron UK Limited
Stroke
1 trial -
Alirocumab (Solution)
Regeneron UK Limited
Hypercholesterolemia
1 trial -
Arm 1 cemiplimab
Regeneron UK Limited
Hepatocellular Carcinoma
1 trial -
Aspirin
Regeneron UK Limited
Healthy Volunteers
1 trial -
BPX-601
Regeneron UK Limited
Prostate Cancer
1 trial -
BPX-601
Regeneron UK Limited
Metastatic Castration-resistant Prostate Cancer
1 trial -
CMP-001
Regeneron UK Limited
Non Small Cell Lung Cancer
1 trial -
CMP-001
Regeneron UK Limited
Malignant Melanoma
1 trial -
Casirivimab and Imdevimab Antibody Cocktail
Regeneron UK Limited
COVID-19
1 trial -
Cemiplimab
Regeneron UK Limited
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
Cemiplimab
Regeneron UK Limited
Anaplastic Thyroid Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Malignancies
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Hormone Receptor-positive Breast Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Epithelial Ovarian Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Lung Cancer
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Merkel Cell Carcinoma
1 trial
Frequently asked questions
How many pipeline programs does Regeneron UK have?
493 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs